Genetics and vaccines in the era of personalized medicine

Current Genomics

Volumn 16, Issue 1, 2015, Pages 47-59

  Castiblanco, John ^a   Anaya, Juan Manuel ^a  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

Author keywords

Autoimmune ecology; Autoimmunity and systems biology; Genetics; HLA; Infection; Personalized medicine; Vaccine

Indexed keywords

CD45 ANTIGEN; CELL SURFACE RECEPTOR; CYTOKINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; TOLL LIKE RECEPTOR; VACCINE; VACCINIA VACCINE;

ALLELE; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DNA MODIFICATION; DNA POLYMORPHISM; DRUG DESIGN; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETICS; HAPLOTYPE; HEREDITY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; PERSONALIZED MEDICINE; SMALLPOX; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS GROUP A;

EID: 84926287802     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202916666141223220551     Document Type: Article

References (105)

1. Andre, F.E. What can be done to make vaccines more trendy? Exp. Rev. Vaccines, 2005, 4 (1), 23-5.
2. Rappuoli, R.; Miller, H.I.; Falkow, S. Medicine. The intangible value of vaccination. Science, 2002, 297 (5583), 937-9.
3. Thomas, C.; Moridani, M. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology, 2010, 278 (2), 204-10.
4. Kaushik, D.K.; Sehgal, D. Developing antibacterial vaccines in genomics and proteomics era. Scandinavian J. Immunol., 2008, 67 (6), 544-52.
5. Plotkin, S.A. Six revolutions in vaccinology. Ped. Infect. Dis. J., 2005, 24 (1), 1-9.
6. Rappuoli, R. From Pasteur to genomics: progress and challenges in infectious diseases. Nature Med., 2004, 10 (11), 1177-85.
7. Projan, S.J.; Nesin, M.; Dunman, P.M. Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr. Opin. Pharmacol., 2006, 6 (5), 473-9.
8. Poland, G.A.; Kennedy, R.B.; McKinney, B.A.; Ovsyannikova, I. G.; Lambert, N.D.; Jacobson, R.M.; Oberg, A.L. Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Seminars Immunol., 2013, 25 (2), 89-103.
9. Fleischmann, R.D.; Adams, M.D.; White, O.; Clayton, R.A.; Kirkness, E.F.; Kerlavage, A.R.; Bult, C.J.; Tomb, J.F.; Dougherty, B.A.; Merrick, J.M. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science, 1995, 269 (5223), 496-512.
10. Fraser, C.M.; Rappuoli, R. Application of microbial genomic science to advanced therapeutics. Ann. Rev. Med., 2005, 56, 459-74.
11. Seib, K.L.; Dougan, G.; Rappuoli, R. The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLoS Genetics, 2009, 5 (10), e1000612.
12. Castiblanco, J.; Arcos-Burgos, M.; Anaya, J.M. What is next after the genes for autoimmunity? BMC Med., 2013, 11, 197.
13. Serruto, D.; Rappuoli, R. Post-genomic vaccine development. FEBS Lett., 2006, 580 (12), 2985-92.
14. Tsang, J.S.; Schwartzberg, P.L.; Kotliarov, Y.; Biancotto, A.; Xie, Z.; Germain, R.N.; Wang, E.; Olnes, M.J.; Narayanan, M.; Golding, H.; Moir, S.; Dickler, H.B.; Perl, S.; Cheung, F.; Baylor, H.C.; Consortium, C.H.I. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell, 2014, 157 (2), 499-513.
15. Pulendran, B.; Li, S.; Nakaya, H.I. Systems vaccinology. Immunity, 2010, 33 (4), 516-29.
16. Shendure, J.; Lieberman Aiden, E. The expanding scope of DNA sequencing. Nat. Biotechnol., 2012, 30 (11), 1084-94.
17. Kann, M.G. Advances in translational bioinformatics: computational approaches for the hunting of disease genes. Briefings Bioin-Form., 2010, 11 (1), 96-110.
18. Chen, R.; Mias, G.I.; Li-Pook-Than, J.; Jiang, L.; Lam, H.Y.; Miriami, E.; Karczewski, K.J.; Hariharan, M.; Dewey, F.E.; Cheng, Y.; Clark, M.J.; Im, H.; Habegger, L.; Balasubramanian, S.; O'Huallachain, M.; Dudley, J.T.; Hillenmeyer, S.; Haraksingh, R.; Sharon, D.; Euskirchen, G.; Lacroute, P.; Bettinger, K.; Boyle, A.P.; Kasowski, M.; Grubert, F.; Seki, S.; Garcia, M.; Whirl-Carrillo, M.; Gallardo, M.; Blasco, M.A.; Greenberg, P.L.; Snyder, P.; Klein, T. E.; Altman, R.B.; Butte, A.J.; Ashley, E.A.; Gerstein, M.; Nadeau, K.C.; Tang, H.; Snyder, M. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell, 2012, 148 (6), 1293-307.
19. Plotkin, S.A. [New vaccination strategies]. Bulletin de l'Academie Nationale de Medecine 2008, 192 (3), 511-8. discussion 518-9.
20. Querec, T.D.; Akondy, R.S.; Lee, E.K.; Cao, W.; Nakaya, H.I.; Teuwen, D.; Pirani, A.; Gernert, K.; Deng, J.; Marzolf, B.; Kennedy, K.; Wu, H.; Bennouna, S.; Oluoch, H.; Miller, J.; Vencio, R.Z.; Mulligan, M.; Aderem, A.; Ahmed, R.; Pulendran, B. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immun., 2009, 10 (1), 116-25.
21. Daar, A. S. Chronic Non-communicable Diseases as a Threat for All: Recent Global Initiatives. Sultan Qaboos Uni. Med. J., 2010, 10 (3), 306-9.
22. Fenner, F. Smallpox and Its Eradication. Aust. Nz. J. Med., 1980, 10 (4), 459-459.
23. Artenstein, A.W.; Poland, G.A. Vaccine history: The past as prelude to the future. Vaccine, 2012, 30 (36), 5299-5301.
24. Norrby, E. Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. J. Exper. Med., 2007, 204 (12), 2779-84.
25. Enders, J.F.; Weller, T.H.; Robbins, F.C. Cultivation of the Lansing Strain of Poliomyelitis Virus in Cultures of Various Human Embryonic Tissues. Science, 1949, 109 (2822), 85-7.
26. Roome, A.J.; Walsh, S.J.; Cartter, M.L.; Hadler, J.L. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA. J. Am. Med. Assoc., 1993, 270 (24), 2931-4.
27. Sette, A.; Rappuoli, R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity, 2010, 33 (4), 530-41.
28. Poland, G. A. Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Am. J. Hum. Gene., 1998, 62 (2), 215-20.
29. Poland, G.A.; Ovsyannikova, I.G.; Jacobson, R.M.; Smith, D.I. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin. Pharmacol. Therap., 2007, 82 (6), 653-64.
30. Poland, G.A.; Ovsyannikova, I.G.; Jacobson, R.M. Personalized vaccines: the emerging field of vaccinomics. Exp. Opin. Biol. Ther., 2008, 8 (11), 1659-67.
31. Ovsyannikova, I.G.; Poland, G.A. Vaccinomics: current findings, challenges and novel approaches for vaccine development. AAPS. J., 2011, 13 (3), 438-44.
32. Patarroyo, M.E.; Bermudez, A.; Patarroyo, M.A. Structural and immunological principles leading to chemically synthesized, multiantigenic, multistage, minimal subunit-based vaccine development. Chem. Rev., 2011, 111 (5), 3459-507.
33. Poland, G.A.; Jacobson, R.M. Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons. Arch. Inter. Med., 1994, 154 (16), 1815-20.
34. Tan, P.L.; Jacobson, R.M.; Poland, G.A.; Jacobsen, S.J.; Pankratz, V.S. Twin studies of immunogenicity--determining the genetic contribution to vaccine failure. Vaccine, 2001, 19 (17-19), 2434-9.
35. Newport, M.J.; Goetghebuer, T.; Weiss, H.A.; Whittle, H.; Siegrist, C.A.; Marchant, A. Genetic regulation of immune responses to vaccines in early life. Genes Immunity, 2004, 5 (2), 122-9.
36. Hohler, T.; Reuss, E.; Evers, N.; Dietrich, E.; Rittner, C.; Freitag, C.M.; Vollmar, J.; Schneider, P.M.; Fimmers, R. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet, 2002, 360 (9338), 991-5.
37. Jacobson, R.M.; Ovsyannikova, I.G.; Targonski, P.V.; Poland, G.A. Studies of twins in vaccinology. Vaccine, 2007, 25 (16), 3160-4.
38. Hirschhorn, J.N.; Gajdos, Z.K. Genome-wide association studies: results from the first few years and potential implications for clinical medicine. Ann. Rev. Med., 2011, 62, 11-24.
39. Crosslin, D.R.; Carrell, D.S.; Burt, A.; Kim, D.S.; Underwood, J.G.; Hanna, D.S.; Comstock, B.A.; Baldwin, E.; de Andrade, M.; Kullo, I.J.; Tromp, G.; Kuivaniemi, H.; Borthwick, K.M.; McCarty, C.A.; Peissig, P.L.; Doheny, K.F.; Pugh, E.; Kho, A.; Pacheco, J.; Hayes, M.G.; Ritchie, M.D.; Verma, S.S.; Armstrong, G.; Stallings, S.; Denny, J.C.; Carroll, R.J.; Crawford, D.C.; Crane, P.K.; Mukherjee, S.; Bottinger, E.; Li, R.; Keating, B.; Mirel, D.B.; Carlson, C.S.; Harley, J.B.; Larson, E.B.; Jarvik, G.P. Genetic variation in the HLA region is associated with susceptibility to herpes zoster. Genes Immunity, 2014, 0.
40. Kennedy, R.B.; Ovsyannikova, I.G.; Haralambieva, I.H.; Lambert, N.D.; Pankratz, V.S.; Poland, G.A. Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients. Immunogenetics, 2014, 66 (7-8), 493-9.
41. Brusic, V.; August, J.T. The changing field of vaccine development in the genomics era. Pharmacogenomics, 2004, 5 (6), 597-600.
42. Mooney, M.; McWeeney, S.; Sekaly, R.P. Systems immunogenetics of vaccines. Seminars Immunol., 2013,25 (2), 124-9.
43. Sinha, P.; Snyder, J.A.; Kim, E.Y.; Moudgil, K.D. The major histocompatibility complex haplotypes dictate and the background genes fine-tune the dominant versus the cryptic response profile of a T-cell determinant within a native antigen: relevance to disease susceptibility and vaccination. Scand. J. Immunol., 2007, 65 (2), 158-65.
44. Abbas, A.K.; Lichtman, A.H. Antigen capture and presentation to lymphocytes. In Basic Immunology: Functions and Disorders of the Immune System, Saunders/Elsevier: 2010; p 45.
45. Shiina, T.; Hosomichi, K.; Inoko, H.; Kulski, J. K., The HLA genomic loci map: expression, interaction, diversity and disease. J. Hum. Genet., 2009, 54 (1), 15-39.
46. Cresswell, P.; Ackerman, A.L.; Giodini, A.; Peaper, D.R.; Wearsch, P.A. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunolog. Rev., 2005, 207, 145-57.
47. Heemels, M.T.; Ploegh, H. Generation, translocation, and presentation of MHC class I-restricted peptides. Ann. Rev. Biochem., 1995,64, 463-91.
48. Williams, A.; Peh, C.A.; Elliott, T. The cell biology of MHC class I antigen presentation. Tissue Antigens, 2002, 59 (1), 3-17.
49. Ghosh, P.; Amaya, M.; Mellins, E.; Wiley, D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLADR3. Nature, 1995, 378 (6556), 457-62.
50. Morris, P.; Shaman, J.; Attaya, M.; Amaya, M.; Goodman, S.; Bergman, C.; Monaco, J.J.; Mellins, E. An essential role for HLADM in antigen presentation by class II major histocompatibility molecules. Nature, 1994, 368 (6471), 551-4.
51. Jacobson, R.M.; Poland, G.A.; Vierkant, R.A.; Pankratz, V.S.; Schaid, D.J.; Jacobsen, S.J.; Sauver, J.S.; Moore, S.B. The association of class I HLA alleles and antibody levels after a single dose of measles vaccine. Hum. Immunol., 2003, 64 (1), 103-9.
52. Ovsyannikova, I.G.; Jacobson, R.M.; Vierkant, R.A.; O'Byrne, M.M.; Poland, G.A. Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine, 2009, 27 (49), 6926-31.
53. Ovsyannikova, I.G.; Jacobson, R.M.; Vierkant, R.A.; Jacobsen, S. J.; Pankratz, V.S.; Poland, G. A. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum. Immunol., 2004, 65 (12), 1506-15.
54. Ovsyannikova, I. G.; Jacobson, R. M.; Ryan, J. E.; Dhiman, N.; Vierkant, R. A.; Poland, G. A. Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination. Clin. Vaccine Immunol. CVI, 2007, 14 (2), 115-22.
55. Deshpande, A.; Wheeler, C.M.; Hunt, W.C.; Peyton, C.L.; White, P.S.; Valdez, Y.E.; Nolan, J.P. Variation in HLA class I antigenprocessing genes and susceptibility to human papillomavirus type 16-associated cervical cancer. J. Infec. Dis., 2008, 197 (3), 371-81.
56. Gostout, B.S.; Poland, G. A.; Calhoun, E.S.; Sohni, Y. R.; Giuntoli, R. L., 2nd; McGovern, R. M.; Sloan, J. A.; Cha, S. S.; Persing, D. H., TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol. Oncol., 2003, 88 (3), 326-32.
57. Shrestha, S.; Wang, C.; Aissani, B.; Wilson, C. M.; Tang, J.; Kaslow, R. A., Interleukin-10 gene (IL10) polymorphisms and human papillomavirus clearance among immunosuppressed adolescents. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007,16 (8), 1626-32.
58. Cho, H. J.; Oh, Y. K.; Kim, Y. B., Advances in human papilloma virus vaccines: a patent review. Exp. Opin. Therap. Pat., 2011, 21 (3), 295-309.
59. Kim, K.S.; Park, S.A.; Ko, K.N.; Yi, S.; Cho, Y.J. Current status of human papillomavirus vaccines. Clin. Experiment. Vaccine Res., 2014, 3 (2), 168-75.
60. Ovsyannikova, I.G.; Jacobson, R.M.; Dhiman, N.; Vierkant, R.A.; Pankratz, V.S.; Poland, G.A. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics, 2008, 121 (5), e1091-9.
61. Ovsyannikova, I.G.; Jacobson, R.M.; Vierkant, R.A.; Jacobsen, S.J.; Pankratz, V.S.; Poland, G.A. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J. Infect. Dis., 2005, 191 (4), 515-9.
62. Ovsyannikova, I.G.; Ryan, J.E.; Vierkant, R.A.; O'Byrne, M.M.; Pankratz, V.S.; Jacobson, R.M.; Poland, G.A. Influence of host genetic variation on rubella-specific T cell cytokine responses following rubella vaccination. Vaccine, 2009, 27 (25-26), 3359-66.
63. Gelder, C.M.; Lambkin, R.; Hart, K.W.; Fleming, D.; Williams, O.M.; Bunce, M.; Welsh, K.I.; Marshall, S.E.; Oxford, J. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J. Infect. Dis., 2002, 185 (1), 114-7.
64. Lambkin, R.; Novelli, P.; Oxford, J.; Gelder, C. Human genetics and responses to influenza vaccination: clinical implications. Am. J. Pharmacogenomics : genomics-related research in drug development and clinical practice 2004,4 (5), 293-8.
65. Ovsyannikova, I.G.; Pankratz, V.S.; Vierkant, R.A.; Jacobson, R.M.; Poland, G.A. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J. Infect. Dis., 2006, 193 (5), 655-63.
66. Ovsyannikova, I.G.; Vierkant, R.A.; Pankratz, V.S.; Jacobson, R.M.; Poland, G.A. Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity. PloS One, 2010, 5 (7), e11806.
67. Sette, A.; Sidney, J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol., 1998, 10 (4), 478-82.
68. Ovsyannikova, I.G.; Jacobson, R.M.; Vierkant, R.A.; Pankratz, V.S.; Poland, G.A. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine, 2007, 25 (16), 3090-100.
69. Johnson, K.L.; Ovsyannikova, I.G.; Poland, G.A.; Muddiman, D.C. Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry. J. Proteome Res., 2005, 4 (6), 2243-9.
70. Jin, P.; Wang, E. Polymorphism in clinical immunology-From HLA typing to immunogenetic profiling. J. Translat. Med., 2003, 1 (1), 8.
71. Dhiman, N.; Ovsyannikova, I.G.; Cunningham, J.M.; Vierkant, R.A.; Kennedy, R.B.; Pankratz, V.S.; Poland, G.A.; Jacobson, R.M. Associations between measles vaccine immunity and singlenucleotide polymorphisms in cytokine and cytokine receptor genes. J. Infect. Dis., 2007, 195 (1), 21-9.
72. Yilmaz, V.; Yentur, S.P.; Saruhan-Direskeneli, G. IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine, 2005, 30 (4), 188-94.
73. Wang, C.; Tang, J.; Song, W.; Lobashevsky, E.; Wilson, C.M.; Kaslow, R.A. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology, 2004, 39 (4), 978-88.
74. Hohler, T.; Reuss, E.; Freitag, C.M.; Schneider, P.M. A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. Hepatology, 2005, 42 (1), 72-6.
75. Dhiman, N.; Haralambieva, I.H.; Kennedy, R.B.; Vierkant, R.A.; O'Byrne, M.M.; Ovsyannikova, I.G.; Jacobson, R.M.; Poland, G.A. SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics, 2010, 62 (4), 197-210.
76. Bowie, A.G.; Haga, I.R. The role of Toll-like receptors in the host response to viruses. Mol. Immunol., 2005, 42 (8), 859-67.
77. Rassa, J.C.; Ross, S.R. Viruses and Toll-like receptors. Micro. Infect. Institut. Past., 2003, 5 (11), 961-8.
78. Dhiman, N.; Ovsyannikova, I.G.; Vierkant, R.A.; Ryan, J.E.; Pankratz, V.S.; Jacobson, R.M.; Poland, G.A. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine, 2008, 26 (14), 1731-6.
79. Ovsyannikova, I.G.; Dhiman, N.; Haralambieva, I.H.; Vierkant, R. A.; O'Byrne, M.M.; Jacobson, R.M.; Poland, G.A. Rubella vaccineinduced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum. Genet., 2010, 127 (2), 207-21.
80. Bieback, K.; Lien, E.; Klagge, I.M.; Avota, E.; Schneider-Schaulies, J.; Duprex, W.P.; Wagner, H.; Kirschning, C.J.; Ter Meulen, V.; Schneider-Schaulies, S. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J. Virol., 2002, 76 (17), 8729-36.
81. Yang, K.; Puel, A.; Zhang, S.; Eidenschenk, C.; Ku, C.L.; Casrouge, A.; Picard, C.; von Bernuth, H.; Senechal, B.; Plancoulaine, S.; Al-Hajjar, S.; Al-Ghonaium, A.; Marodi, L.; Davidson, D.; Speert, D.; Roifman, C.; Garty, B.Z.; Ozinsky, A.; Barrat, F.J.; Coffman, R.L.; Miller, R.L.; Li, X.; Lebon, P.; Rodriguez-Gallego, C.; Chapel, H.; Geissmann, F.; Jouanguy, E.; Casanova, J.L. Human TLR-7-,-8-, and-9-mediated induction of IFN-alpha/beta and-lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity, 2005, 23 (5), 465-78.
82. Hahm, B.; Cho, J.H.; Oldstone, M.B. Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. Virology, 2007, 358 (2), 251-7.
83. Dhiman, N.; Poland, G.A.; Cunningham, J.M.; Jacobson, R.M.; Ovsyannikova, I.G.; Vierkant, R.A.; Wu, Y.; Pankratz, V.S. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J. Aller. Clin. Immunol., 2007, 120 (3), 666-72.
84. Anaya, J.M. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmunity Rev., 2012, 11 (11), 781-4.
85. Cunningham, M.W.; McCormack, J.M.; Talaber, L.R.; Harley, J.B.; Ayoub, E.M.; Muneer, R.S.; Chun, L.T.; Reddy, D.V. Human monoclonal antibodies reactive with antigens of the group A Streptococcus and human heart. J. Immunol., 1988, 141 (8), 2760-6.
86. Cunha-Neto, E.; Duranti, M.; Gruber, A.; Zingales, B.; De Messias, I.; Stolf, N.; Bellotti, G.; Patarroyo, M.E.; Pilleggi, F.; Kalil, J. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. Proc. Nat. Acad. Sci. U. S. A., 1995, 92 (8), 3541-5.
87. Chen, J.; Field, J.A.; Glickstein, L.; Molloy, P.J.; Huber, B.T.; Steere, A.C. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheumatism, 1999, 42 (9), 1813-22.
88. Vucic, S.; Kiernan, M.C.; Cornblath, D.R. Guillain-Barre syndrome: an update. J. Clin. Neurosci. Official J. Neurosurgical Soc. Australasia, 2009, 16 (6), 733-41.
89. Goldberg, E.; Krause, I. Infection and type 1 diabetes mellitus-a two edged sword? Autoimmunity Rev., 2009, 8 (8), 682-6.
90. Ercolini, A.M.; Miller, S.D. The role of infections in autoimmune disease. Clin. Experiment. Immunol., 2009,155 (1), 1-15.
91. Zandman-Goddard, G.; Berkun, Y.; Barzilai, O.; Boaz, M.; Blank, M.; Ram, M.; Sherer, Y.; Anaya, J. M.; Shoenfeld, Y. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann. New York Acad. Sci., 2009, 1173, 658-63.
92. Omer, S.B. Safety of quadrivalent human papillomavirus vaccine. J. Inter. Med., 2012, 271 (2), 177-8.
93. Orbach, H.; Tanay, A. Vaccines as a trigger for myopathies. Lupus, 2009, 18 (13), 1213-6.
94. Chao, C.; Klein, N.P.; Velicer, C.M.; Sy, L.S.; Slezak, J.M.; Takhar, H.; Ackerson, B.; Cheetham, T.C.; Hansen, J.; Deosaransingh, K.; Emery, M.; Liaw, K.L.; Jacobsen, S.J. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J. Internal Med., 2012, 271 (2), 193-203.
95. Arnheim-Dahlstrom, L.; Pasternak, B.; Svanstrom, H.; Sparen, P.; Hviid, A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ, 2013, 347, f5906.
96. Grimaldi-Bensouda, L.; Guillemot, D.; Godeau, B.; Benichou, J.; Lebrun-Frenay, C.; Papeix, C.; Labauge, P.; Berquin, P.; Penfornis, A.; Benhamou, P.Y.; Nicolino, M.; Simon, A.; Viallard, J.F.; Costedoat-Chalumeau, N.; Courcoux, M.F.; Pondarre, C.; Hilliquin, P.; Chatelus, E.; Foltz, V.; Guillaume, S.; Rossignol, M.; Abenhaim, L. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J. Internal Med., 2014, 275 (4), 398-408.
97. Cardenas-Roldan, J.; Rojas-Villarraga, A.; Anaya, J.M. How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med., 2013, 11, 73.
98. Langer-Gould, A.; Qian, L.; Tartof, S.Y.; Brara, S. M.; Jacobsen, S. J.; Beaber, B.E.; Sy, L.S.; Chao, C.; Hechter, R.; Tseng, H.F. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA. Neurol., 2014, 71 (12), 1506-13.
99. Israeli, E.; Agmon-Levin, N.; Blank, M.; Shoenfeld, Y. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin. Rev. Aller. Immunol., 2011, 41 (2), 163-8.
100. [100] Guis, S.; Pellissier, J.F.; Nicoli, F.; Reviron, D.; Mattei, J.P.; Gherardi, R.K.; Pelletier, J.; Kaplanski, G.; Figarella-Branger, D.; Roudier, J. HLA-DRB1*01 and macrophagic myofasciitis. Arthritis Rheumatism, 2002, 46 (9), 2535-7.
101. [101] Shoenfeld, Y.; Agmon-Levin, N. 'ASIA'-autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmunity, 2011, 36 (1), 4-8.
102. [102] Partinen, M.; Kornum, B.R.; Plazzi, G.; Jennum, P.; Julkunen, I.; Vaarala, O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet. Neurology 2014, 13 (6), 600-13.
103. [103] Gaucher, D.; Therrien, R.; Kettaf, N.; Angermann, B.R.; Boucher, G.; Filali-Mouhim, A.; Moser, J.M.; Mehta, R.S.; Drake, D.R. 3rd; Castro, E.; Akondy, R.; Rinfret, A.; Yassine-Diab, B.; Said, E.A.; Chouikh, Y.; Cameron, M.J.; Clum, R.; Kelvin, D.; Somogyi, R.; Greller, L.D.; Balderas, R.S.; Wilkinson, P.; Pantaleo, G.; Tartaglia, J.; Haddad, E.K.; Sekaly, R.P. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Experimen. Med., 2008, 205 (13), 3119-31.
104. [104] Bashford-Rogers, R.J.; Palser, A.L.; Idris, S.F.; Carter, L.; Epstein, M.; Callard, R.E.; Douek, D.C.; Vassiliou, G.S.; Follows, G.A.; Hubank, M.; Kellam, P. Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods. BMC Immunol., 2014, 15 (1), 29.
105. [105] Anaya, J.M.; Shoenfeld, Y.; Rojas-Villarraga, A.; Levy, R.A.; Cervera, R. Autoimmunity. From Bench to Bedside; Universidad del Rosario: Bogota, 2013.